tjlpa Profile

Latest Blog Posts

• Asbestos ban to be announced by federal government next week
  on Dec 15, 2016 in Exposure Facts asbestos asbestos exposure asbestos fibers asbestos products asbestos-cancer asbestos-related disease canada
  The federal government plans to announce a comprehensive ban on asbestos in Canada next week, CBC News has learned. The country currently allows imports of construction products and automotive parts that contain the toxic fibre, even though Canada no...
• Canada should stop importing deadly asbestos, labour group says
  on Dec 9, 2016 in Facts asbestos asbestos exposure asbestos fibers asbestos mine asbestos products asbestos-cancer asbestos-related disease canada
  The Canadian Labour Congress is calling for a ban on asbestos. Exposure to asbestos — a fibrous mineral used in building and construction — is the leading cause of workplace-related death in Canada. Canada stopped exporting asbestos in 2011, and...
• Treatments to prolong life for mesothelioma patients closer
  on Nov 15, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma mesothelioma treatment
  Researchers have uncovered a strange way that asbestos-related tumours grow, which could pave the way towards better treatments. The scientists at Adelaide’s Flinders University have found that malignant mesothelioma tumours are able to transfo...
• New Paradigms in the Treatment of Mesothelioma and NSCLC: An Overview by Fred Hirsch
  on Nov 11, 2016 in Medicine asbestos-cancer asbestos-related disease malignant mesothelioma mesothelioma treatment
  Dr. Haffizulla: Welcome to PracticeUpdate. I’m Dr. Farzanna Haffizulla. Joining me today is Dr. Fred Hirsch, CEO of the International Association for the Study of Lung Cancer, and Professor of Medicine at the University of Colorado in Denver. Dr.
• Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma
  on Nov 10, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma pleural-mesothelioma
  Malignant pleural mesothelioma shows marked cytoarchitectural diversity. The aim of the study was to evaluate how morphological phenotype impacted upon overall survival. 191 cases of malignant pleural mesothelioma with available follow-up were identi...
• Residual fibre lung burden among patients with pleural mesothelioma who have been occupationally exposed to asbestos
  on Nov 8, 2016 in Exposure Facts Medicine asbestos asbestos exposure asbestos fibers malignant mesothelioma mesothelioma pleural-mesothelioma
  Objectives  To evaluate the lungs asbestos fibres concentration in participants with malignant pleural mesothelioma (MPM) who have been occupationally exposed. Methods  The lung samples were obtained from pleuropneumonectomies or autopsies of 271 m...
• Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy
  on Nov 2, 2016 in Medicine asbestos malignant mesothelioma mesothelioma mesothelioma treatment
  Pemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene. Recently, we emphasi...
• Arginine Deprivation for Malignant Pleural Mesothelioma
  on Oct 26, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma mesothelioma treatment pleural-mesothelioma
  Arginine deprivation is a novel anticancer strategy in argininosuccinate synthetase 1 (ASS1)–negative tumors. In a multicenter, phase II trial, immunohistochemistry identified 68 patients with ASS1 deficiency among 201 patients with malignant pleur...
• Scientists discover new option for treating malignant pleural mesothelioma
  on Oct 24, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma mesothelioma treatment
  Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. For the first time in the world, they were able to show in a preclinical study, both...
• Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review
  on Oct 19, 2016 in Medicine asbestos-cancer malignant mesothelioma mesothelioma pleural-mesothelioma
  Abstract Background Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5–10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or...
• Asbestos-related cancer costs Canadians billions
  on Oct 13, 2016 in Facts asbestos asbestos claims asbestos disease asbestos exposure asbestos lawsuits asbestos-cancer asbestos-related disease canada lung cancer lung disease
  A first-ever estimate of the toll of asbestos-related cancers on society pegs the cost of new cases at $1.7-billion per year in Canada, and notes that is likely an under-estimate. The economic burden of lung cancer and mesothelioma from work-related...
• Lawyers For Plaintiffs And Drug Company Merck Make Their Arguments To Third Circuit Appeals Court In Fosamax - Femur Fracture Litigation
  on Jan 20, 2016 in Legal Case Updates Side Effect: Bone Disease (osteonecrosis, osteomyelitis, drug-related fracture) drug injury FDA federal court MDL femur fractures Fosamax impossibility preemption label changes law lawsuits legal appeals Merck arguments side effects Third Circuit warnings
  One Of The Legal Issues Is Whether Merck Could Have And Should Have Strengthened The Drug Label Warnings About This Apparent Side Effect, Or Not (Posted by Tom Lamb at DrugInjuryWatch.com) The title of out last article about the Fosamax drug injury l...
• Eliquis, Savaysa, And Xarelto: New Blood Thinner Drugs Feared By Many Doctors Because No Antidote Is Available When Needed
  on Jan 7, 2016 in Side Effect: Bleeding Events (hemorrhage, overanticoagulation) anticolagulation drugs antidotes apixaban blood thinners Bristol-Myers Squibb Daiichi Sankyo drug injury edoxaban Eliquis Janssen Pharmaceuticals lawsuits major bleeding Pfizer rivaroxaban Savaysa side effects Xarelto
  Some Recent Articles Point Out the Real Problems And Consequences Of Major Bleeding Events Involving Eliquis, Savaysa, And Xarelto (Posted by Tom Lamb at DrugInjuryWatch.com) As many of you know from direct-to-consumer advertising on television, ther...
• FDA Adds Ketoacidosis Warnings To Diabetes Drugs Invokana, Farxiga, And Jardiance As Well As Other SGLT2 Inhibitors
  on Dec 8, 2015 in Drug Safety Alerts FDA Drug Safety Oversight Health Canada News Side Effect: Blood-acid Disorders (acidosis, ketoacidosis, ketosis) Side Effect: Kidney Injury (acute renal failure, kidney transplant) acute renal failure diabetes drugs drug injury drug label changes Farxiga FDA Forxiga Glyxambi Health Canada increased risks Invokamet Invokana ketoacidosis kidney failure kidney problems lawsuits safety issues SGLT2 inhibitor side effects Sodium Glucose Cotransporter 2 Inhibitorsacuters Synjardy Xigduo XR
  This Follows October 2015 Safety Alert By Health Canada Concerning Increased Risks Of Kidney Problems (Posted by Tom Lamb at DrugInjuryWatch.com) In December 2015 the FDA issued a Drug Safety Communication concerning the risk of ketoacidosis, a serio...
• Is Eliquis Safer Than Xarelto And Pradaxa If It Causes Fewer Dangerous Major Bleeding Events
  on Nov 10, 2015 in Pharma Industry Trends Side Effect: Bleeding Events (hemorrhage, overanticoagulation) acute bleed antidote drug injury Eliquis major bleeding events personal injury Pradaxa Praxbind reversal agent Savaysa wrongful death Xarelto
  Perhaps, But Neither Eliquis Nor Xarelto Have Any Specific Reversal Agent To Stop An Acute Bleed Once It Starts; Only Pradaxa Does (Posted by Tom Lamb at DrugInjuryWatch.com) During the American Heart Association 2015 Scientific Sessions in Orlando,...
• Zofran: MDL No. 2657 Pending In Massachusetts With Judge Dennis Saylor Presiding Over These Drug Injury Birth Defects Lawsuits
  on Nov 3, 2015 in Legal Case Updates Side Effect: Birth Defects (abnormality, congenital malformation) birth defects cleft lip congenital malformations cleft palate drug Injury federal court MDL GlaxoSmithKline GSK heart-related problems Judge Dennis Saylor lawsuits Massachusetts Ondansetron Zofran
  Women Who Used Zofran Had Babies With Cleft Palate / Cleft Lip, Various Types Of Heart-Related Problems, And Other Congenital Malformations (Posted by Tom Lamb at DrugInjuryWatch.com) In July 2015 the drug company GlaxoSmithKline (GSK) filed a motion...
• Hepatitis C Drugs Viekira Pak And Technivie Require Warnings Label Changes Due To Liver Injury Reports
  on Oct 26, 2015 in Drug Safety Alerts Side Effect: Liver Failure (hepatitis, acute liver failure, liver transplant) drug labels changes drug safety drug-induced liver injury FDA hepatitis C drugs liver damage side effects Technivie Viekira Pak warnings
  FDA Says The Timing Of Liver Injury Suggests That These Are Side Effects, Especially In Patients With Advanced Cirrhosis (Posted by Tom Lamb at DrugInjuryWatch.com) Viekira Pak and Technivie are relatively new drugs used to treat chronic hepatitis C.
• Bayer's Corporate Reports About Their YAZ / Yasmin Settlement Program Show Progress Continues To Be Made, Albeit At A Slow Pace
  on Oct 19, 2015 in Legal Case Updates Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT) Bayer Beyaz corporate reports drug injury Gianvi lawsuits litigation mediations numbers of cases Ocella Safyral settlements updates Yasmin YAZ
  First Lawsuits In The YAZ / Yasmin / Gianvi / Ocella / Beyaz / Safyral Drug Injury Litigation Were Filed In 2009, With Thousands Of Cases Still Pending (Posted by Tom Lamb at DrugInjuryWatch.com) The most recent Bayer information about the YAZ / Yasm...
• Xarelto, Savaysa, Pradaxa, And Eliquis: Safety Secondary To Ease Of Use Is "A Major Wrong Turn" Says Drug Watchdog Group
  on Oct 9, 2015 in Drug Safety Alerts FDA Drug Safety Oversight Side Effect: Bleeding Events (hemorrhage, overanticoagulation) adverse drug reactions anticoagulants antiplatelet agents aspirin clopidogrel deaths drug injury Eliquis FDA gastrointestinal bleeds intracranial bleeding nonsteroidal anti-inflammatory drugs NSAIDS platelet inhibitors Plavix Pradaxa Savaysa side effects Xarelto
  This New Generation Of Oral Anticoagulants Has Bleeding-Related Adverse Reactions Including Gastrointestinal And Intracranial Bleeds (Posted by Tom Lamb at DrugInjuryWatch.com) The ISMP QuarterWatch published on September 23, 2015 includes an examina...
• New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With "joint pain that can be severe and disabling"
  on Aug 28, 2015 in Drug Safety Alerts FDA Drug Safety Oversight Side Effect: Joint Problems (arthralgia, joint pain, arthritis) arthralgia diabetes drugs dipeptidyl peptidase-4 inhibitors DPP-4 drug class drug injury drug safety FDA warnings Januvia joint pains label changes Nesina Onglyza side effects Tradjenta
  Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced that it has found indications of a ne...